Company intelligence / Profile preview

L&Z

Ownership: Private
Development stage: Commercial

Overview

L&J Bio is developing a dual-action recombinant fusion protein therapy that targets both amyloid-beta aggregation and tau neurofibrillary tangles in Alzheimer’s disease. Their lead candidate, AL04, is engineered to cross the blood-brain barrier and act directly within brain tissue. The company has secured a recent U.S. patent supporting its technology and seeks investment/licensing partners. No published clinical results yet; programs are at preclinical or IND-enabling stage

Therapeutic areas: Neurology
Modalities: Recombinant fusion proteinBiologicProtein
Industry: Biotech

Partnerships

Seeking licensing/collaboration with larger pharmaceutical companiesNo major partnerships publicly announced as of June 2025.

Beyond the preview

Go deeper on L&Z.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L&Z.

Explore the full profile